

February 19, 2025

Dear VFC Provider,

The 2024-2025 seasonal administration of nirsevimab (Beyfortus® [Sanofi and AstraZeneca]) in 50 mg and 100 mg doses ends in our region on March 31, 2025. The Centers for Disease Control and Prevention (CDC) does not recommend administration of nirsevimab after this date.

Nirsevimab ordering for administration to VFC-eligible children through the New York City (NYC) Department of Health and Mental Hygiene's <u>Online Registry</u> will end on February 28, 2025. To ensure your facility has enough nirsevimab before the ordering cut-off, please place orders as soon as possible.

Under current CDC guidance, unexpired and properly stored nirsevimab, received during the 2024-2025 respiratory syncytial virus (RSV) season, is viable for the following 2025-2026 RSV season. To safeguard the product's viability, VFC providers must adhere to the following storage and handling requirements:

- Keep refrigerated at 36°F to 46°F (2°C to 8°C).
- May be kept at room temperature 68°F to 77°F (20°C to 25°C) for a maximum of 8 hours.
- After removal from the refrigerator, must be used within 8 hours or discarded.
- Store in the original package to protect from light until time of use.
- Do not freeze or expose to heat.
- Do not use beyond the expiration date shown on the vial label.

Further information on nirsevimab recommendations—both clinical guidance and storage and handling requirements—is available on the CDC webpage for healthcare providers <u>RSV Immunization Guidance</u> for Infants and Young Children | <u>RSV | CDC</u>.

For questions on RSV immunization of young children, please call (347) 396-2400 or email <u>nycimmunize@health.nyc.gov</u>. As a reminder, office hours for all NYC immunizing providers take place on the first Wednesday of each month from 12:00PM to 1:00PM.

We thank you for protecting NYC children from vaccine-preventable diseases.

Sincerely,

The day Crow

Bindy Crouch, MD, MPH Assistant Commissioner Bureau of Immunization